TrialThe Journal of clinical endocrinology and metabolism2020

Cardiovascular Benefit of Empagliflozin Across the Spectrum of Cardiovascular Risk Factor Control in the EMPA-REG OUTCOME Trial.

Silvio E Inzucchi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.